Biomolecules & Therapeutics

  • 제32권6호
  • /
  • Pages.793-800
  • /
  • 2024
  • /
  • 1976-9148(pISSN)
  • /
  • 2005-4483(eISSN)
한국응용약물학회 (The Korean Society of Applied Pharmacology)
권호 표지
DOI QR코드

DOI QR Code

Jolkinolide B Ameliorates Liver Inflammation and Lipogenesis by Regulating JAK/STAT3 Pathway

  • Hye-Rin Noh (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Guoyan Sui (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Jin Woo Lee (College of Pharmacy, Duksung Women's University) ;
  • Feng Wang (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Jeong-Su Park (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Yuanqiang Ma (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Hwan Ma (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Ji-Won Jeong (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Dong-Su Shin (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Xuefeng Wu (Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Immunology, Department of Immunology and Microbiology, Hongqiao International Institute of Medicine, Shanghai Ton-gren Hospital, Shanghai Jiao Tong University School of Medicine) ;
  • Bang-Yeon Hwang (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Yoon Seok Roh (College of Pharmacy and Medical Research Center, Chungbuk National University)
  • 투고 : 2024.02.27
  • 심사 : 2024.07.02
  • 발행 : 2024.11.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Hepatic dysregulation of lipid metabolism exacerbates inflammation and enhances the progression of metabolic dysfunction-associated steatotic liver disease (MASLD). STAT3 has been linked to lipid metabolism and inflammation. Jolkinolide B (JB), derived from Euphorbia fischeriana, is known for its pharmacological anti-inflammatory and anti-tumor properties. Therefore, this study investigated whether JB affects MASLD prevention by regulating STAT3 signaling. JB attenuated steatosis and inflammatory responses in palmitic acid (PA)-treated hepatocytes. Additionally, JB treatment reduced the mRNA expression of de-novo lipogenic genes, such as acetyl-CoA carboxylase and stearoyl-CoA desaturase 1. Interestingly, JB-mediated reduction in inflammation and lipogenesis was dependent on STAT3 signaling. JB consistently modulated mitochondrial dysfunction and the mRNA expression of inflammatory cytokines by inhibiting PA-induced JAK/STAT3 activation. This study suggests that JB is a potential therapeutic agent to prevent major stages of MASLD through inhibition of JAK/STAT3 signaling in hepatocytes.

키워드

과제정보

This research was supported by National Research Foundation of Korea (2017R1A5A2015541), Korean Food and Drug Administration (20182MFDS425), Regional Innovation Strategy (RIS) of National Research Foundation of Korea (2021RIS-001), Chungbuk National University BK21 program (2023).

참고문헌

  1. Abd El-Kader, S. M. and El-Den Ashmawy, E. M. (2015) Non-alcoholic fatty liver disease: the diagnosis and management. World J. Hepatol. 7, 846-858.
  2. Chen, X., Li, L., Liu, X., Luo, R., Liao, G., Li, L., Liu, J., Cheng, J., Lu, Y. and Chen, Y. (2018) Oleic acid protects saturated fatty acid mediated lipotoxicity in hepatocytes and rat of non-alcoholic steatohepatitis. Life Sci. 203, 291-304.
  3. Flowers, M. T. and Ntambi, J. M. (2008) Role of stearoyl-coenzyme A desaturase in regulating lipid metabolism. Curr. Opin .Lipidol. 19, 248-256.
  4. Geng, Y., Faber, K. N., de Meijer, V. E., Blokzijl, H. and Moshage, H. (2021) How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? Hepatol. Int. 15, 21-35.
  5. Geng, Z. F., Liu, Z. L., Wang, C. F., Liu, Q. Z., Shen, S. M., Liu, Z. M., Du, S. S. and Deng, Z. W. (2011) Feeding deterrents against two grain storage insects from Euphorbia fischeriana. Molecules 16, 466-476.
  6. Hu, X., Li, J., Fu, M., Zhao, X. and Wang, W. (2021) The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct. Target. Ther. 6, 402.
  7. Kojta, I., Chacinska, M. and Blachnio-Zabielska, A. (2020) Obesity, bioactive lipids, and adipose tissue inflammation in insulin resistance. Nutrients 12, 32375231.
  8. Leyane, T. S., Jere, S. W. and Houreld, N. N. (2022) Oxidative stress in ageing and chronic degenerative pathologies: molecular mechanisms involved in counteracting oxidative stress and chronic inflammation. Int J. Mol. Sci. 23, 35806275.
  9. Liang, Y., Zhang, Z., Tu, J., Wang, Z., Gao, X., Deng, K., El-Samahy, M. A., You, P., Fan, Y. and Wang, F. (2021) gamma-Linolenic acid prevents lipid metabolism disorder in palmitic acid-treated alpha mouse liver-12 cells by balancing autophagy and apoptosis via the LKB1-AMPK-mTOR pathway. J. Agric. Food Chem. 69, 8257-8267.
  10. Liu, Y., Li, D., Wang, S., Peng, Z., Tan, Q., He, Q. and Wang, J. (2023) 6-Gingerol ameliorates hepatic steatosis, inflammation and oxidative stress in high-fat diet-fed mice through activating LKB1/AMPK signaling. Int. J. Mol. Sci. 24, 37047258.
  11. Makri, E. S., Makri, E. and Polyzos, S. A. (2022) Combination therapies for nonalcoholic fatty liver disease. J. Pers. Med. 12, 35887662.
  12. Quan, Y., Xin, Y., Tian, G., Zhou, J. and Liu, X. (2020) Mitochondrial ROS-modulated mtDNA: a potential target for cardiac aging. Oxid. Med. Cell. Longev. 2020, 9423593.
  13. Quiros, P. M., Goyal, A., Jha, P. and Auwerx, J. (2017) Analysis of mtDNA/nDNA ratio in mice. Curr. Protoc. Mouse Biol. 7, 47-54.
  14. Shen, L., Zhang, S. Q., Liu, L., Sun, Y., Wu, Y. X., Xie, L. P. and Liu, J. C. (2017) Jolkinolide A and Jolkinolide B inhibit proliferation of A549 cells and activity of human umbilical vein endothelial cells. Med. Sci. Monit. 23, 223-237.
  15. Teng, M. L., Ng, C. H., Huang, D. Q., Chan, K. E., Tan, D. J., Lim, W. H., Yang, J. D., Tan, E. and Muthiah, M. D. (2023) Global incidence and prevalence of nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 29, S32-S42.
  16. Vuppalanchi, R. and Chalasani, N. (2009) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 49, 306-317.
  17. Wang, H. B., Chu, W. J., Wang, Y., Ji, P., Wang, Y. B., Yu, Q. and Qin, G. W. (2010) Diterpenoids from the roots of Euphorbia fischeriana. J. Asian Nat. Prod. Res. 12, 1038-1043.
  18. Wang, Q., Wang, Z., Xu, M., Tu, W., Hsin, I. F., Stotland, A., Kim, J. H., Liu, P., Naiki, M., Gottlieb, R. A. and Seki, E. (2020) Neurotropin inhibits lipid accumulation by maintaining mitochondrial function in hepatocytes via AMPK activation. Front. Physiol. 11, 950.
  19. Wang, Y., Shen, S. Y., Liu, L., Zhang, X. D., Liu, D. Y., Liu, N., Liu, B. H. and Shen, L. (2022) Jolkinolide B inhibits proliferation or migration and promotes apoptosis of MCF-7 or BT-474 breast cancer cells by downregulating the PI3K-Akt pathway. J. Ethnopharmacol. 282, 114581.
  20. Yang, W., Zhu, L., Lai, S., Ding, Q., Xu, T., Guo, R., Dou, X., Chai, H., Yu, Z. and Li, S. (2022) Cimifugin ameliorates lipotoxicity-induced hepatocyte damage and steatosis through TLR4/p38 MAPK- and SIRT1-involved pathways. Oxid. Med. Cell. Longev. 2022, 4557532.
  21. Zhao, Z., Deng, Z. T., Huang, S., Ning, M., Feng, Y., Shen, Y., Zhao, Q. S. and Leng, Y. (2022) Alisol B alleviates hepatocyte lipid accumulation and lipotoxicity via regulating RARalpha-PPARgamma-CD36 cascade and attenuates non-alcoholic steatohepatitis in mice. Nutrients 14, 35745142.